Home › NDC Lookup › Ingredients › Hydroxyzine Hydrochloride › 59651-0500-99
Hydroxyzine Hydrochloride 25 mg Tablet, Film Coated, 1,000-count — NDC 59651-0500-99 package photo

Hydroxyzine Hydrochloride 25 mg Tablet, Film Coated, 1,000-count

by Aurobindo Pharma Limited · 1000 TABLET, FILM COATED in 1 BOTTLE (59651-500-99)
NDC 59651-0500-99
🏷️ FDA NDC (as labeled) 59651-500-99 billing pads the product segment with a zero
This package
Contains1,000-count Cost per ea$0.0326 NADAC Per package$32.60 / 1000 tablets Pack sizes4 compare ↓
Also priced by: Medicaid pays $0.2067/unit · Part D plans $0.1378/unit — full pricing hub ↓
Also comes in: 100 tablets 59651-0500-01 500 tablets 59651-0500-05 8000 tablets 59651-0500-81
On market Non-controlled
🗂️ Data synced Sep 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

⚠️
Other active recalls for Hydroxyzine Hydrochloride (different manufacturers) — 1 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class III · Jun 2, 2026 — Presence of foreign substance (ANI Pharmaceuticals, Inc.) · FDA recall D-0619-2026
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

🆔 Identity & classification

FDA NDC (as labeled) 59651-500-99
Product NDC 59651-500
11-digit billing NDC 59651050099
NCPDP billing unit EA — each (per item)
SPL Set ID 9de2de56-614f-4294-8794-d30758cf5f70
DEA schedule Non-controlled
Marketing category DRUG FOR FURTHER PROCESSING
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2021-10-07
Dosage form TABLET, FILM COATED
Substance HYDROXYZINE DIHYDROCHLORIDE
GPI-14 57200040100310
GCN Seq No 003728
GCN 13943
HICL code 001608
Ingredient (HICL) Hydroxyzine Hcl
HIC1 code Z
Therapeutic class — broad (HIC1) Body As A Whole
HIC2 code Z2
Therapeutic class — intermediate (HIC2) Antihistamines, Antiserotonins, Immunosuppressants
HIC3 code Z2P
Therapeutic class — specific (HIC3) Antihistamines - 1St Generation
AHFS code 04:04.00.00
AHFS class First Generation Antihistamines
FDB label name HYDROXYZINE HCL 25 MG TABLET
FDB brand name Hydroxyzine Hcl
Legend status F — Federal legend — prescription drug or device
Why two NDCs? The FDA registers this code as 59651-500-99 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 59651-0500-99. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

🏭 Manufacturer & labeler

LabelerAurobindo Pharma Limited
Labeler code59651
First marketedOct 2021
Product typeDrug For Further Processing
Portfolio1,456 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

🩺 Clinical

Label name HYDROXYZINE HCL 25 MG TABLET Ingredient Hydroxyzine Hcl
📖 What it is MedlinePlus · NLM

Hydroxyzine is used to relieve itching caused by allergic skin reactions, to relieve anxiety and tension, and as a sedative before and after general anesthesia for surgery. Hydroxyzine is in a class of medications called antihistamines. It works by blocking the action of histamine, a substance in the body that causes allergic symptoms. It also works by decreasing activity in the brain.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • Hydroxyzine is most often used to relieve anxiety and tension, or to control itching from allergic conditions like hives or eczema. It's also used as a calming medication before su...
  • Drowsiness is the most common side effect — it's actually how the medication works, so some sleepiness is expected, especially when you first start. For most people it gets better...
  • This is really important to go over with your pharmacist or doctor, because hydroxyzine interacts with a number of common drugs. Combining it with alcohol, opioid pain medicines, s...
  • Can I take hydroxyzine with my other medications?
📖 Read our full Hydroxyzine guide →

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

💊 What it looks like

Color Purple
ShapeRound
Imprint7
Size8 mm
ScoringNot scored
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

🧪 Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII ECW0LZ41X8
    A synthetic red dye used to color tablets and capsules. It helps make medicines visually distinctive so patients can easily identify their medication.
  • UNII 4AQJ3LG584
    A synthetic blue dye combined with aluminum to create a stable colorant. It's used in medicines and supplements to add blue color or create specific shades for product identification and appearance.
  • UNII 0VUT3PMY82
    Hypromellose 2910 is a plant-derived thickening agent made from cellulose. In medicines, it forms protective coatings on tablets or capsules, controls how fast the drug releases, and thickens liquid formulations.
  • UNII 3NXW29V3WO
    Hypromellose is a plant-based thickener made from cellulose. It's used in medicines as a binder to hold ingredients together, a coating for tablets, and a thickener for liquids.
  • UNII EWQ57Q8I5X
    Lactose monohydrate is a natural sugar derived from milk. It serves as a filler and binder in tablets and capsules, helping create the proper size, texture, and consistency of the medicine.
  • UNII 70097M6I30
    Magnesium stearate is a salt made from magnesium and stearic acid, a fatty substance. It's used in tablets and capsules as a lubricant and glidant to help ingredients flow smoothly during manufacturing and prevent sticking.
  • UNII 7T9FYH5QMK
    A plant-derived powder that serves as a binder and filler in tablets and capsules. It helps hold ingredients together, adds bulk, and aids in smooth tablet disintegration when swallowed.
  • UNII 3WJQ0SDW1A
    Polyethylene glycol is a synthetic liquid or solid polymer used in medicines as a solvent, lubricant, and humectant. It helps dissolve active ingredients, reduces friction during manufacturing, and retains moisture in the final product.
  • UNII 6OZP39ZG8H
    Polysorbate 80 is a synthetic emulsifier derived from sorbitol and oleic acid. It helps mix oil and water-based ingredients together in medications and improves how the product disperses in the body.
  • UNII O8232NY3SJ
    A plant-based carbohydrate derived from corn kernels. It acts as a filler to add bulk, a binder to hold ingredients together, and a disintegrant to help the tablet break apart in your stomach for absorption.
  • UNII 15FIX9V2JP
    Titanium dioxide is a bright white mineral powder commonly used as a colorant and opacifying agent. It makes pills and tablets white or lighter in color and helps make coatings non-transparent.

11 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

💲 Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.033 $32.60 / 1000 tablets
Medicaid paysCMS SDUD · 12 mo $0.2067 $206.70 / 1000 tablets
Medicare drug plans payPart D · Q2 2026 $0.1378 $137.80 / 1000 tablets
Medicare Part B allowsASP · Q0177 No ASP payment limit on file for Q0177 this quarter.
NADAC price history (per ea) — tap or hover for the price & month
Dec 2025 Mar 2026 Jun 2026 Sep 2026 $0.036 $0.033
▼ Down 7% over the last 10 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

🧾 Billing & reimbursement

FDA NDC (as labeled)59651-500-99
11-digit billing NDC59651-0500-99
Format5-3-2 as registered → padded to 5-4-2 for billing (zero added to the product segment)
HCPCS J-codeQ0177
DescriptorHYDROXYZINE PAMOATE, 25 MG, ORAL, FDA APPROVED PRESCRIPTION ANTI-EMETIC, FOR USE AS A COMPLETE THERAPEUTIC SUBSTITUTE FOR AN IV ANTI-EMETIC AT THE TIME OF CHEMOTHERAPY TREATMENT, NOT TO EXCEED A 48 HOUR DOSAGE REGIMEN
Billing units / pkg1 units
Crosswalk sourcePDAC NDC-HCPCS crosswalk (DME MAC / DMEPOS)
Where does this data come from?
The HCPCS J-code crosswalk comes from the CMS ASP NDC-HCPCS crosswalk and the DMEPDAC (DME MAC) NDC-HCPCS crosswalk — free public CMS data. Billing units are derived from the code’s descriptor and the package amount.

🔁 Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Hydroxyzine Hydrochloride 25 mg 00093-5061-01 Teva 100 tablets $0.033 AB Availability likely —
Hydroxyzine hydrochloride 25 mg 00904-7378-40 Major 500 tablets $0.033 AB Availability likely —
Hydroxyzine Hydrochloride 25 mg 10702-0011-01 KVK-Tech, 100 tablets $0.033 AB Availability likely —
Hydroxyzine Hydrochloride 25 mg 16571-0114-01 Rising 100 tablets $0.033 AB Availability likely —
HydrOXYzine Hydrochloride 25 mg 16714-0082-10 Northstar 100 tablets $0.033 AB Availability likely —
Hydroxyzine hydrochloride 25 mg 23155-0501-01 Heritage 100 tablets $0.033 AB Availability likely —
Hydroxyzine Hydrochloride 25 mg 24658-0782-10 PURACAP 1000 tablets $0.033 AB Availability likely —
Hydroxyzine Hydrochloride 25 mgthis 59651-0500-99 Aurobindo 1000 tablets $0.033 — Availability likely —
Hydroxyzine Hydrochloride 25 mg 60687-0675-01 American 1 tablet $0.033 AB Availability likely —
Hydroxyzine Hydrochloride 25 mg 62135-0574-05 Chartwell 500 tablets $0.033 AB Availability likely —
Hydroxyzine Hydrochloride 25 mg 00904-6617-61 Major 1 tablet $0.034 AB Discontinued +5%
Hydroxyzine Hydrochloride 25 mg 42806-0160-01 Epic 100 tablets $0.034 AB Availability likely +5%
Hydroxyzine hydrochloride 25 mg 00615-8082-05 NCS 15 tablets — AB FDA listed —
Hydroxyzine Hydrochloride 25 mg 10135-0811-01 Marlex 100 tablets — AB FDA listed —
Hydroxyzine Hydrochloride 25 mg 11534-0205-01 Sunrise 100 tablets — AB FDA listed —
Hydroxyzine Hydrochloride 25 mg 31722-0501-01 Camber 100 tablets — AB FDA listed —
Hydroxyzine Hydrochloride 25 mg 43063-0518-06 PD-Rx 6 tablets — — FDA listed —
Hydroxyzine Hydrochloride 25 mg 43063-0627-28 PD-Rx 28 tablets — AB FDA listed —
Hydroxyzine Hydrochloride 25 mg 43063-0962-01 PD-Rx 100 tablets — — FDA listed —
Hydroxyzine hydrochloride 25 mg 45865-0675-20 Medsource 20 tablets — AB FDA listed —
Hydroxyzine hydrochloride 25 mg 50090-2648-00 A-S 20 tablets — AB FDA listed —
Hydroxyzine hydrochloride 25 mg 50090-3583-01 A-S 28 tablets — AB FDA listed —
Hydroxyzine hydrochloride 25 mg 50090-5297-00 A-S 90 tablets — AB FDA listed —
Hydroxyzine hydrochloride 25 mg 50090-6624-00 A-S 90 tablets — AB FDA listed —
HydrOXYzine Hydrochloride 25 mg 50090-6626-00 A-S 90 tablets — AB FDA listed —
HydrOXYzine Hydrochloride 25 mg 50090-6628-00 A-S 90 tablets — AB FDA listed —
Hydroxyzine Hydrochloride 25 mg 50090-6653-01 A-S 28 tablets — — FDA listed —
Hydroxyzine Hydrochloride 25 mg 50090-6655-00 A-S 20 tablets — — FDA listed —
Hydroxyzine Hydrochloride 25 mg 50090-6657-00 A-S 90 tablets — — FDA listed —
Hydroxyzine Hydrochloride 25 mg 50090-6659-00 A-S 90 tablets — — FDA listed —
Hydroxyzine Hydrochloride 25 mg 50090-7034-00 A-S 1 tablet — — FDA listed —
Hydroxyzine Hydrochloride 25 mg 50090-7327-00 A-S 90 tablets — AB FDA listed —
Hydroxyzine Hydrochloride 25 mg 50090-7329-00 A-S 90 tablets — AB FDA listed —
Hydroxyzine Hydrochloride 25 mg 50090-7330-00 A-S 20 tablets — AB FDA listed —
Hydroxyzine Hydrochloride 25 mg 50090-7331-00 A-S 30 tablets — AB FDA listed —
Hydroxyzine Hydrochloride 25 mg 50090-7332-00 A-S 30 tablets — AB FDA listed —
HydrOXYzine Hydrochloride 25 mg 50090-7582-01 A-S 28 tablets — AB FDA listed —
Hydroxyzine hydrochloride 25 mg 51407-0970-10 Golden 1000 tablets — AB FDA listed —
Hydroxyzine hydrochloride 25 mg 51655-0080-20 Northwind 20 tablets — AB FDA listed —
Hydroxyzine Hydrochloride 25 mg 51655-0589-52 Northwind 30 tablets — AB FDA listed —
Hydroxyzine Hydrochloride 25 mg 55154-2148-00 Cardinal 1 tablet — AB FDA listed —
Hydroxyzine Hydrochloride 25 mg 55154-7994-00 Cardinal 1 tablet — AB Discontinued —
Hydroxyzine Hydrochloride 25 mg 60760-0971-30 St. 30 tablets — AB FDA listed —
Hydroxyzine Hydrochloride 25 mg 60760-0990-30 St. 30 tablets — AB FDA listed —
Hydroxyzine Hydrochloride 25 mg 62135-0546-05 Chartwell 500 tablets — AB FDA listed —
Hydroxyzine hydrochloride 25 mg 63187-0733-20 Proficient 20 tablets — AB FDA listed —
Hydroxyzine hydrochloride 25 mg 63629-1856-01 Bryant 30 tablets — AB FDA listed —
Hydroxyzine Hydrochloride 25 mg 63629-8740-01 Bryant 100 tablets — AB FDA listed —
Hydroxyzine Hydrochloride 25 mg 65162-0671-10 Amneal 100 tablets — — FDA listed —
Hydroxyzine hydrochloride 25 mg 67046-0713-03 Coupler 30 tablets — AB FDA listed —
Hydroxyzine Hydrochloride 25 mg 67046-1311-03 Coupler 30 tablets — AB FDA listed —
HydrOXYzine Hydrochloride 25 mg 68071-2237-02 NuCare 20 tablets — AB FDA listed —
HydrOXYzine Hydrochloride 25 mg 68071-3450-04 NuCare 4 tablets — AB FDA listed —
Hydroxyzine Hydrochloride 25 mg 68071-3964-03 NuCare 30 tablets — AB FDA listed —
Hydroxyzine Hydrochloride 25 mg 68071-4622-03 NuCare 30 tablets — — FDA listed —
Hydroxyzine hydrochloride 25 mg 68071-5286-03 NuCare 30 tablets — AB FDA listed —
Hydroxyzine Hydrochloride 25 mg 68071-5296-06 NuCare 6 tablets — AB FDA listed —
Hydroxyzine hydrochloride 25 mg 68788-7854-03 Preferred 30 tablets — AB FDA listed —
Hydroxyzine Hydrochloride 25 mg 68788-8707-03 Preferred 30 tablets — AB FDA listed —
Hydroxyzine hydrochloride 25 mg 70518-1692-01 REMEDYREPACK 15 tablets — AB Discontinued —
Hydroxyzine Hydrochloride 25 mg 70518-1730-01 REMEDYREPACK 30 tablets — — Discontinued —
Hydroxyzine Hydrochloride 25 mg 70518-2066-00 REMEDYREPACK 30 tablets — AB FDA listed —
Hydroxyzine Hydrochloride 25 mg 70518-2279-01 REMEDYREPACK 30 tablets — AB Discontinued —
Hydroxyzine Hydrochloride 25 mg 70518-4141-00 REMEDYREPACK 30 tablets — AB FDA listed —
Hydroxyzine Hydrochloride 25 mg 71205-0155-20 Proficient 20 tablets — AB FDA listed —
Hydroxyzine Hydrochloride 25 mg 71205-0273-15 Proficient 15 tablets — — FDA listed —
Hydroxyzine Hydrochloride 25 mg 71335-0935-01 Bryant 30 tablets — AB FDA listed —
Hydroxyzine Hydrochloride 25 mg 71335-1047-01 Bryant 30 tablets — — FDA listed —
Hydroxyzine hydrochloride 25 mg 71335-2340-01 Bryant 30 tablets — AB FDA listed —
Hydroxyzine Hydrochloride 25 mg 71335-2451-01 Bryant 30 tablets — AB FDA listed —
Hydroxyzine Hydrochloride 25 mg 71335-2776-01 Bryant 30 tablets — AB FDA listed —
Hydroxyzine Hydrochloride 25 mg 71335-3035-01 Bryant 1000 tablets — AB FDA listed —
HydrOXYzine Hydrochloride 25 mg 71610-0686-53 Aphena 60 tablets — AB FDA listed —
Hydroxyzine Hydrochloride 25 mg 71610-0735-30 Aphena 30 tablets — — FDA listed —
Hydroxyzine hydrochloride 25 mg 71610-0844-53 Aphena 60 tablets — AB FDA listed —
Hydroxyzine hydrochloride 25 mg 71610-0851-30 Aphena 30 tablets — AB FDA listed —
Hydroxyzine Hydrochloride 25 mg 72162-1333-02 Bryant 20 tablets — — FDA listed —
Hydroxyzine Hydrochloride 25 mg 72162-2512-00 Bryant 1000 tablets — AB FDA listed —
Hydroxyzine Hydrochloride 25 mg 72789-0216-12 PD-Rx 12 tablets — AB FDA listed —
Hydroxyzine hydrochloride 25 mg 76420-0882-01 Asclemed 100 tablets — AB FDA listed —
Hydroxyzine hydrochloride 25 mg 80425-0365-01 Advanced 30 tablets — AB FDA listed —
Hydroxyzine Hydrochloride 25 mg 80425-0590-01 Advanced 30 tablets — AB FDA listed —
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

⏳ Availability & generic status

🏛️
2021
On the market since
Oct 2021
📍
2026
Currently FDA-listed
5 years listed
🔓
·
Generic versions listed
see equivalents
✅Generic appears available

FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available — see Therapeutic equivalents.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

🗺️ Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for 59651-0500-99, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
17.9K
Units reimbursed last 4 qtrs
1M
Gross reimbursed last 4 qtrs
$210.2K
Avg / prescription
$11.76
Avg / unit
$0.2067
Latest quarter Q1 2026
2.8KRx
Medicaid pays / ea
$0.2067
gross reimbursed
vs
NADAC / ea
$0.0326
acquisition cost
=
Spread
+$0.1741
+534% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
40% FFS 60% MCO
Fee-for-service · 7,059 Rx Managed care · 10,810 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: 5,261 units · 67.3 per 100k residents WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: 11,894 units · 207 per 100k residents MN Wisconsin: no data reported WI Michigan: 6,629 units · 66.0 per 100k residents MI New York: 47,668 units · 244 per 100k residents NY Vermont: 4,988 units · 771 per 100k residents VT New Hampshire: no data reported NH Oregon: no data reported OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: 1,080 units · 118 per 100k residents SD Iowa: 827 units · 25.8 per 100k residents IA Illinois: 1,996 units · 15.9 per 100k residents IL Indiana: 2,665 units · 38.8 per 100k residents IN Ohio: 49,904 units · 423 per 100k residents OH Pennsylvania: 27,613 units · 213 per 100k residents PA New Jersey: 15,462 units · 166 per 100k residents NJ Massachusetts: no data reported MA California: 27,983 units · 71.8 per 100k residents CA Utah: no data reported UT Colorado: 313 units · 5.3 per 100k residents CO Nebraska: no data reported NE Missouri: 84,414 units · 1,362 per 100k residents MO Kentucky: 24,335 units · 538 per 100k residents KY West Virginia: 2,926 units · 165 per 100k residents WV Virginia: 6,057 units · 69.5 per 100k residents VA Maryland: 4,604 units · 74.5 per 100k residents MD Connecticut: 5,242 units · 145 per 100k residents CT Rhode Island: no data reported RI Arizona: 17,386 units · 234 per 100k residents AZ New Mexico: 15,103 units · 714 per 100k residents NM Kansas: 9,089 units · 309 per 100k residents KS Arkansas: 32,608 units · 1,063 per 100k residents AR Tennessee: 76,119 units · 1,068 per 100k residents TN North Carolina: 3,247 units · 30.0 per 100k residents NC South Carolina: 598 units · 11.1 per 100k residents SC Delaware: 880 units · 85.4 per 100k residents DE Oklahoma: 164,667 units · 4,063 per 100k residents OK Louisiana: 292,617 units · 6,397 per 100k residents LA Mississippi: 34,174 units · 1,162 per 100k residents MS Alabama: 18,431 units · 361 per 100k residents AL Georgia: 14,169 units · 128 per 100k residents GA D.C.: no data reported DC Hawaii: no data reported HI Texas: no data reported TX Florida: 5,855 units · 25.9 per 100k residents FL
Units reimbursed · per 100k residents
5.36,397
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Louisiana 6,397 /100k
2 Oklahoma 4,063 /100k
3 Missouri 1,362 /100k
4 Mississippi 1,162 /100k
5 Tennessee 1,068 /100k
6 Arkansas 1,063 /100k
7 Vermont 771 /100k
8 New Mexico 714 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

💊 Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
500 tablets59651-0500-05 214,150 Rx · $1,841,552
1000 tablets this page59651-0500-99 17,869 Rx · $210,177
100 tablets59651-0500-01 1,312 Rx · $13,606
8000 tablets59651-0500-81 No Medicaid data
Drug total (last 4 qtrs): 233,331 Rx · 14,088,261 units · $2,065,335 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

📦 Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startStatus
59651-0500-01 100 TABLET, FILM COATED in 1 BOTTLE (59651-500-01) $0.0326 / ea $3.26 2021-10-07 Active
59651-0500-05 500 TABLET, FILM COATED in 1 BOTTLE (59651-500-05) $0.0326 / ea $16.28 2021-10-07 Active
59651-0500-99 You're viewing this 1000 TABLET, FILM COATED in 1 BOTTLE (59651-500-99) $0.0326 / ea $32.55 2021-10-07 Active
59651-0500-81 8000 TABLET, FILM COATED in 1 BAG (59651-500-81) — — — Active

You're viewing one of 4 pack sizes for this product.

This pack effectively ties for the lowest per-ea cost of the 3 priced pack sizes ($0.0326 NADAC).

This pack accounts for about 7.7% of this product's recent Medicaid fills; most go to the 500 tablets pack. See all packs ↓

Pack size FAQ

What quantity is in NDC 59651-0500-99?
NDC 59651-0500-99 is a 1,000-count package — 1000 tablet, film coated in 1 bottle.
What is the difference between NDC 59651-0500-99 and NDC 59651-0500-01?
Both are Hydroxyzine Hydrochloride 25 mg Tablet, Film Coated — the drug itself is identical. NDC 59651-0500-99 is the 1,000-count package, while NDC 59651-0500-01 is the 100 tablets package.
What NDC number is used to bill for this package of Hydroxyzine Hydrochloride 25 mg Tablet, Film Coated?
Bill NDC 59651-0500-99 — the 11-digit billing format is 59651050099. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

🧭 About this NDC listing & data coverage

Listed for further processing / repackaging

What "drug for further processing" means

FDA lists this package under the "drug for further processing" marketing category: Aurobindo Pharma Limited supplies it to other companies for further processing or repackaging (blister cards that are later repackaged or co-packaged are a common example). The units themselves are a finished dosage form — which is why pricing or Medicaid data can still appear — but this exact package code may not be the presentation a retail pharmacy dispenses.

What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos ✓ Available
Inactive ingredients (structured) ✓ Available
NADAC pharmacy acquisition price (CMS) ✓ Available
Orange Book / therapeutic-equivalence data — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope.
HCPCS J-code billing crosswalk ✓ Available
Medicaid utilization (CMS SDUD) ✓ Available
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Is this NDC FDA-approved?
An NDC listing does not by itself establish FDA approval — the NDC Directory records that a product is listed with FDA, not that it was reviewed and approved. This listing's marketing category is "Drug For Further Processing". Products approved under an application carry an NDA, ANDA, or BLA number.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The FDA registers it as 59651-500-99, which is what is printed on the packaging and shown on DailyMed. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero: 59651-0500-99, written without dashes as 59651050099. The Identity section at the top of this page lists every form of this code.
What do the three segments of this NDC mean?
In 59651-0500-99, the first segment (59651) is the labeler code FDA assigned to Aurobindo Pharma Limited; the middle segment (0500) identifies this specific product — its ingredient, strength, and dosage form; and the last segment (99) identifies this exact package size and type. Together they name one specific package of one specific product.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Aurobindo Pharma Limited. Listing status can change — the directory data on this page refreshes weekly.
Does this product come in other package sizes?
Yes — the FDA directory lists 3 other package presentations of this same product, including 100 tablets (59651-0500-01), 500 tablets (59651-0500-05), 8000 tablets (59651-0500-81). Each has its own NDC and its own page — see the package list near the top of this page.
Who lists this product with the FDA?
Aurobindo Pharma Limited is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Does this product have a billing J-code?
Yes — this NDC cross-references HCPCS code Q0177 for medical-claim billing (typically used when a product is administered in a clinical setting rather than dispensed at a retail pharmacy). See the Billing section on this page.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.

📄 Full FDA label FDA SPL

The complete FDA label for this product, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications ⚠️ Warnings 🤒 Adverse Reactions 🧓 Geriatric Use 🆘 Overdosage 🧬 Clinical Pharmacology 📦 How Supplied / Storage and Handling 📋 Description
🎯 Indications and Usage 156 words ▾

INDICATIONS AND USAGE For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested. Useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses and in histamine-mediated pruritus. As a sedative when used as a premedication and following general anesthesia, hydroxyzine may potentiate meperidine and barbiturates , so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis.

Atropine and other belladonna alkaloids are not affected by the drug. Hydroxyzine is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent. The effectiveness of hydroxyzine as an antianxiety agent for long term use, that is more than 4 months, has not been assessed by systematic clinical studies.

The physician should reassess periodically the usefulness of the drug for the individual patient.

⏱️ Dosage and Administration 165 words ▾

DOSAGE AND ADMINISTRATION For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested: adults, 50 to 100 mg q.i.d.; children under 6 years, 50 mg daily in divided doses; children over 6 years, 50 to 100 mg daily in divided doses. For use in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses and in histamine-mediated pruritus: adults, 25 mg t.i.d. or q.i.d.; children under 6 years, 50 mg daily in divided doses; children over 6 years, 50 to 100 mg daily in divided doses.

As a sedative when used as a premedication and following general anesthesia: 50 to 100 mg for adults and 0.6 mg/kg of body weight in children. When treatment is initiated by the intramuscular route of administration, subsequent doses may be administered orally. As with all potent medication, the dosage should be adjusted according to the patient's response to therapy.

⛔ Contraindications 104 words ▾

CONTRAINDICATIONS Oral hydroxyzine hydrochloride is contraindicated in patients with known hypersensitivity to hydroxyzine hydrochloride products, and in patients with known hypersensitivity to cetirizine hydrochloride or levocetirizine hydrochloride. Hydroxyzine is contraindicated in patients with a prolonged QT interval. Hydroxyzine, when administered to the pregnant mouse, rat, and rabbit induced fetal abnormalities in the rat and mouse at doses substantially above the human therapeutic range.

Clinical data in human beings are inadequate to establish safety in early pregnancy. Until such data are available, hydroxyzine is contraindicated in early pregnancy. Hydroxyzine is contraindicated for patients who have shown a previous hypersensitivity to any component of this medication.

⚠️ Warnings 29 words ▾

WARNINGS Nursing Mothers It is not known whether this drug is excreted in human milk. Since many drugs are so excreted, hydroxyzine should not be given to nursing mothers.

🤒 Adverse Reactions 128 words ▾

ADVERSE REACTIONS Side effects reported with the administration of hydroxyzine hydrochloride are usually mild and transitory in nature. Anticholinergic: Dry mouth. Central Nervous System: Drowsiness is usually transitory and may disappear in a few days of continued therapy or upon reduction of dose.

Involuntary motor activity including rare instances of tremor and convulsions have been reported, usually with doses considerably higher than those recommended. Clinically significant respiratory depression has not been reported at recommended doses. Cardiac System: QT prolongation, Torsade de Pointes.

In postmarketing experience, the following additional undesirable effects have been reported: Body as a Whole: Allergic reaction. Nervous System: Headache. Psychiatric: Hallucination.

Skin and Appendages: Oral hydroxyzine is associated with Acute Generalized Exanthematous Pustulosis (AGEP) and fixed drug eruptions in post marketing reports; pruritus, rash, urticaria.

🧓 Geriatric Use ~1 min read ▾

Geriatric Use A determination has not been made whether controlled clinical studies of hydroxyzine included sufficient numbers of subjects aged 65 and over to define a difference in response from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.

The extent of renal excretion of hydroxyzine has not been determined. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selections. Sedating drugs may cause confusion and over sedation in the elderly; elderly patients generally should be started on low doses of hydroxyzine and observed closely.

Acute Generalized Exanthematous Pustulosis (AGEP) Hydroxyzine may rarely cause Acute Generalized Exanthematous Pustulosis (AGEP), a serious skin reaction characterized by fever and numerous small, superficial, non-follicular, sterile pustules, arising within large areas of edematous erythema. Inform patients about the signs of AGEP, and discontinue hydroxyzine at the first appearance of a skin rash, worsening of pre-existing skin reactions which hydroxyzine may be used to treat, or any other sign of hypersensitivity.

If signs or symptoms suggest AGEP, use of hydroxyzine should not be resumed and alternative therapy should be considered. Avoid cetirizine or levocetirizine in patients who have experienced AGEP or other hypersensitivity reactions with hydroxyzine, due to the risk of cross-sensitivity .

🆘 Overdosage 174 words ▾

OVERDOSAGE The most common manifestation of hydroxyzine overdosage is hypersedation. Other reported signs and symptoms were convulsions, stupor, nausea and vomiting. As in the management of overdosage with any drug, it should be borne in mind that multiple agents may have been taken.

If vomiting has not occurred spontaneously, it should be induced. Immediate gastric lavage is also recommended. General supportive care, including frequent monitoring of the vital signs and close observation of the patient, is indicated.

Hypotension, though unlikely, may be controlled with intravenous fluids and levarterenol or metaraminol. Do not use epinephrine as hydroxyzine counteracts its pressor action. Hydroxyzine overdose may cause QT prolongation and Torsade de Pointes.

ECG monitoring is recommended in cases of hydroxyzine overdose. There is no specific antidote. It is doubtful that hemodialysis would be of any value in the treatment of overdosage with hydroxyzine.

However, if other agents such as barbiturates have been ingested concomitantly, hemodialysis may be indicated. There is no practical method to quantitate hydroxyzine in body fluids or tissue after its ingestion or administration.

🧬 Clinical Pharmacology 130 words ▾

CLINICAL PHARMACOLOGY Hydroxyzine hydrochloride is unrelated chemically to the phenothiazines, reserpine, meprobamate or the benzodiazepines. Hydroxyzine is not a cortical depressant, but its action may be due to a suppression of activity in certain key regions of the subcortical area of the central nervous system. Primary skeletal muscle relaxation has been demonstrated experimentally.

Bronchodilator activity, and antihistaminic and analgesic effects have been demonstrated experimentally and confirmed clinically. An antiemetic effect, both by the apomorphine test and the veriloid test, has been demonstrated. Pharmacological and clinical studies indicate that hydroxyzine in therapeutic dosage does not increase gastric secretion or acidity and in most cases has mild antisecretory activity.

Hydroxyzine is rapidly absorbed from the gastrointestinal tract and hydroxyzine’s clinical effects are usually noted within 15 to 30 minutes after oral administration.

📦 How Supplied / Storage and Handling 204 words ▾

HOW SUPPLIED Hydroxyzine Hydrochloride Tablets USP, 10 mg are lavender, round, biconvex, film- coated tablets debossed with "1" on one side and plain on other side. They are supplied as follows: Bottles of 100 NDC 59651-499-01 Bottles of 500 NDC 59651-499-05 Bottles of 1,000 NDC 59651-499-99 Blister of 10x10 Unit-Dose Tablets NDC 59651-499-78 Hydroxyzine Hydrochloride Tablets USP, 25 mg are lavender, round, biconvex, film- coated tablets debossed with "2" on one side and plain on other side. They are supplied as follows: Bottles of 100 NDC 59651-500-01 Bottles of 500 NDC 59651-500-05 Bottles of 1,000 NDC 59651-500-99 Hydroxyzine Hydrochloride Tablets USP, 50 mg are purple, round, biconvex, film-coated tablets debossed with "7" on one side and plain on other side.

They are supplied as follows: Bottles of 100 NDC 59651-501-01 Bottles of 500 NDC 59651-501-05 Bottles of 1,000 NDC 59651-501-99 STORAGE Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Dispense in a tight container as defined in the USP, with a child-resistant closure (as required). KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.

Distributed by: Aurobindo Pharma USA, Inc. 279 Princeton-Hightstown Road East Windsor, NJ 08520 Manufactured by: Aurobindo Pharma Limited Hyderabad-500 032, India Revised: 10/2021

📋 Description 104 words ▾

DESCRIPTION Hydroxyzine hydrochloride has the chemical name of 2-[2-[4-( p -Chloro-α-phenylbenzyl)-1-piperazinyl] ethoxy] ethanol dihydrochloride. C 21 H 27 ClN 2 O 2 •2HCl Molecular Weight 447.83 Hydroxyzine hydrochloride USP occurs as a white powder which is very soluble in water. Each tablet for oral administration contains 10 mg, 25 mg or 50 mg hydroxyzine hydrochloride USP.

Inactive ingredients include FD&C blue #2 aluminum lake, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate 80, pregelatinized starch (corn), and titanium dioxide. In addition, 10 mg contains D&C red #30 aluminum lake, 25 mg and 50 mg contains D&C red #7 calcium lake. CHEMICAL STRUCTURE

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗
← 59651-0499-01 · Aurobindo 59651-0501-01 · Aurobindo →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.